Zobrazeno 1 - 10
of 2 986
pro vyhledávání: '"Wierda, W"'
Autor:
Zhang R; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khare P; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Banerjee P; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Medical Physiology, College of Medicine, Texas A&M University Health Science Center, Bryan, TX, USA., Ivan C; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Caris Life Sciences, Irving, TX, USA., Schneider S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA., Barbaglio F; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., Clise-Dwyer K; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jensen VB; Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thompson E; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mendoza M; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chiorazzi N; Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.; Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Uniondale, NY, USA.; Departments of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Uniondale, NY, USA.; Northwell Health Cancer Institute, Lake Success, NY, USA., Chen SS; Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA., Yan XJ; Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ghia P; B cell neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.; Università Vita-Salute San Raffaele, Milan, Italy., Caligaris-Cappio F; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.; AIRC (Associazione Italiana per la Ricerca sul Cancro), 20123, Milan, Italy., Mendonsa R; Navan Technologies, Inc, San Carlos, CA, USA., Kasimsetty S; Navan Technologies, Inc, San Carlos, CA, USA., Swoboda R; Navan Technologies, Inc, San Carlos, CA, USA., Bayraktar R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gandhi V; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Calin GA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Keating MJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bertilaccio MTS; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. MSBertilaccio@mdanderson.org.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2024 Oct 23; Vol. 14 (1), pp. 168. Date of Electronic Publication: 2024 Oct 23.
Autor:
Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA. fravandi@mdanderson.org., Senapati J; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Issa G; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Balkin H; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Garris R; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX, USA.
Publikováno v:
Leukemia [Leukemia] 2024 Sep 25. Date of Electronic Publication: 2024 Sep 25.
Autor:
Marvin-Peek J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jen WY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McCue D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haddad FG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burger J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Abusab T; Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA., Jorgensen J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., O'Brien S; Department of Medicine, UCI Health Chao Family Comprehensive Cancer Center, Orange, CA, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
Leukemia & lymphoma [Leuk Lymphoma] 2024 Sep; Vol. 65 (9), pp. 1325-1334. Date of Electronic Publication: 2024 May 15.
Autor:
Marvin-Peek J; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, jmarvin@mdanderson.org., Shelton V; Department of Nursing, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Brassil K; Pack Health, A Quest Diagnostics Company, Birmingham, Alabama, USA., Fellman B; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Barr A; Pack Health, A Quest Diagnostics Company, Birmingham, Alabama, USA., Chien KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hammond D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Swaminathan M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., DiNardo C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Publikováno v:
Acta haematologica [Acta Haematol] 2024 Jun 11, pp. 1-10. Date of Electronic Publication: 2024 Jun 11.
Autor:
Kittai AS; Division of Hematology, The Ohio State University, Columbus, OH., Bond D; Division of Hematology, The Ohio State University, Columbus, OH., Huang Y; Division of Hematology, The Ohio State University, Columbus, OH., Bhat SA; Division of Hematology, The Ohio State University, Columbus, OH., Blyth E; Blood Transplant and Cell Therapies Program, Westmead Hospital Department of Haematology, Westmead, NSW, Australia., Byrd JC; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH., Chavez JC; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Dela Cruz JP; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Dowling MR; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Melbourne, Australia., Duffy C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Ho C; Clinical Research Division, Fred Hutchinson Cancer Center and University of Washington, Seattle, WA., Jacobson C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Jaglowski S; Division of Hematology, The Ohio State University, Columbus, OH., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Lin KH; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Miller C; Department of Pathology, The Ohio State University, Columbus, OH., McCarthy C; Department of Hematology, Department of Clinical Informatics, City of Hope National Medical Center, Duarte, CA., Omer Z; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH., Parry E; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Rai M; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR., Rogers KA; Division of Hematology, The Ohio State University, Columbus, OH., Saha A; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL., Schachter L; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR., Scott H; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Senapati J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Shadman M; Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Melbourne, Australia., Siddiqi T; Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA., Stephens DM; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., Vanguru V; Institute of Haematology, Royal Prince Alfred Hospital, NSW, Australia., Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Woyach JA; Division of Hematology, The Ohio State University, Columbus, OH., Thompson PA; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Melbourne, Australia.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jun 10; Vol. 42 (17), pp. 2071-2079. Date of Electronic Publication: 2024 Mar 29.
Autor:
Wierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, Alessandra, Badoux, X. C., Kuss, B. J., Jackson, S., Moreno, Carol, Jacobs, R. M. D., Pagel, J. M., Flinn, I., Pak, Y., Zhou, Cathy, Szafer-Glusman, E., Ninomoto, J., Dean, James P, James, D. F., Ghia, Paolo, Tam, C. S., Universitat Autònoma de Barcelona
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 34
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
PURPOSE CAPTIVATE ( NCT02910583 ), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c35a6a06435710a766e71312c7d53b84
https://doi.org/10.1200/jco.21.00807
https://doi.org/10.1200/jco.21.00807
Autor:
Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Morita K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., DiNardo C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Bravo GM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Pierce SA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Soltysiak KA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Tingen MS; Cancer Prevention, Control, & Population Health Program, Georgia Cancer Center, Augusta University, Augusta, GA; Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA., Cortes JE; Georgia Cancer Center, Augusta, GA. Electronic address: jorge.cortes@augusta.edu.
Publikováno v:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Nov; Vol. 23 (11), pp. e369-e378. Date of Electronic Publication: 2023 Aug 06.
Autor:
Parry EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Lemvigh CK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Health Technology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark., Deng S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dangle N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ruthen N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Knisbacher BA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Broséus J; Inserm UMRS1256 Nutrition-Génétique et Exposition Aux Risques Environnementaux (N-GERE), Université de Lorraine, 54000 Nancy, France; Université de Lorraine, CHRU-Nancy, Service d'hématologie Biologique, Pôle Laboratoires, 54000 Nancy, France., Hergalant S; Inserm UMRS1256 Nutrition-Génétique et Exposition Aux Risques Environnementaux (N-GERE), Université de Lorraine, 54000 Nancy, France., Guièze R; CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France; EA 7453 (CHELTER), Université Clermont Auvergne, 63001 Clermont-Ferrand, France., Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Zhang W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Johnson C; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Long JM; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA; Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA 02115, USA., Yin S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Werner L; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Anandappa A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Purroy N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gohil S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Oliveira G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA., Bachireddy P; Department of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Shukla SA; Department of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Huang T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Khoury JD; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA., Thakral B; Department of Hematopathology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Dickinson M; Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Tam C; Alfred Health, Melbourne, VIC, Australia; Monash University, Melbourne, VIC, Australia., Livak KJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Getz G; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Neuberg D; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Feugier P; Inserm UMRS1256 Nutrition-Génétique et Exposition Aux Risques Environnementaux (N-GERE), Université de Lorraine, 54000 Nancy, France; Université de Lorraine, CHRU Nancy, service d'hématologie clinique, Nancy, France., Kharchenko P; Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02215, USA., Wierda W; Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Olsen LR; Department of Health Technology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark., Jain N; Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: Catherine_wu@dfci.harvard.edu.
Publikováno v:
Cancer cell [Cancer Cell] 2023 Oct 09; Vol. 41 (10), pp. 1803-1816.e8. Date of Electronic Publication: 2023 Sep 21.
Autor:
Bazinet A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Wang W; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Jorgensen J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Patel K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., DiNardo C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Haddad FG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Nogueras Gonzalez G; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Thompson P; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Publikováno v:
Blood advances [Blood Adv] 2023 Jul 11; Vol. 7 (13), pp. 3284-3296.
Autor:
Jabbour E; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ejabbour@mdanderson.org., Short NJ; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Senapati J; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jain N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang X; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo CD; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wierda W; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Montalban Bravo G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sasaki K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia TM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khoury J; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang SA; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haddad FG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jacob J; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garris R; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
The Lancet. Haematology [Lancet Haematol] 2023 Jun; Vol. 10 (6), pp. e433-e444. Date of Electronic Publication: 2023 May 12.